Orphan Drugs: Fda Could Improve Designation Review Consistency; Rare Disease Drug Development Challenges Continue

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.